BR112016011430A2 - agentes anticâncer e preparação dos mesmos. - Google Patents
agentes anticâncer e preparação dos mesmos.Info
- Publication number
- BR112016011430A2 BR112016011430A2 BR112016011430A BR112016011430A BR112016011430A2 BR 112016011430 A2 BR112016011430 A2 BR 112016011430A2 BR 112016011430 A BR112016011430 A BR 112016011430A BR 112016011430 A BR112016011430 A BR 112016011430A BR 112016011430 A2 BR112016011430 A2 BR 112016011430A2
- Authority
- BR
- Brazil
- Prior art keywords
- preparation
- anticancer agents
- anticancer
- agents
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361906133P | 2013-11-19 | 2013-11-19 | |
US61/906,133 | 2013-11-19 | ||
PCT/US2014/066458 WO2015077370A1 (en) | 2013-11-19 | 2014-11-19 | Anti-cancer agents and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016011430A2 true BR112016011430A2 (pt) | 2017-09-12 |
BR112016011430B1 BR112016011430B1 (pt) | 2022-09-13 |
Family
ID=53180106
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016011430-2A BR112016011430B1 (pt) | 2013-11-19 | 2014-11-19 | Compostos, conjugado de anticorpo, composição farmacêutica os compreendendo e seus usos |
Country Status (20)
Country | Link |
---|---|
US (1) | US10000505B2 (pt) |
EP (1) | EP3071563B1 (pt) |
JP (2) | JP6937578B2 (pt) |
KR (1) | KR102428737B1 (pt) |
CN (3) | CN105829299A (pt) |
AU (1) | AU2014353087B2 (pt) |
BR (1) | BR112016011430B1 (pt) |
CA (1) | CA2931111C (pt) |
CL (1) | CL2016001209A1 (pt) |
DK (1) | DK3071563T3 (pt) |
EA (1) | EA035262B1 (pt) |
ES (1) | ES2943711T3 (pt) |
FI (1) | FI3071563T3 (pt) |
IL (2) | IL245637B (pt) |
MX (1) | MX2016006591A (pt) |
MY (1) | MY189459A (pt) |
PE (1) | PE20161240A1 (pt) |
PH (1) | PH12016500924A1 (pt) |
PT (1) | PT3071563T (pt) |
WO (1) | WO2015077370A1 (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3071563B1 (en) | 2013-11-19 | 2023-04-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
WO2017214423A2 (en) * | 2016-06-08 | 2017-12-14 | William Marsh Rice University | Derivatives of thailanstatin a, methods of treatment and methods of synthesis thereof |
AU2017331260B2 (en) | 2016-09-23 | 2024-11-07 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
MX2020003089A (es) | 2017-09-20 | 2020-10-15 | Ph Pharma Co Ltd | Analogos de tailanstatina. |
CN109020876A (zh) * | 2018-09-21 | 2018-12-18 | 大连理工大学 | 一种新型6-羟基-2h-二氢吡啶-3-酮的制备方法 |
CN115698018A (zh) * | 2020-04-09 | 2023-02-03 | 百时美施贵宝公司 | 美亚霉素类似物和使用方法 |
CN113563361B (zh) * | 2021-08-17 | 2022-05-20 | 浙江珲达生物科技有限公司 | 一种从伯克霍尔德菌发酵液提取fr901464的方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901464A (fr) | 1943-01-23 | 1945-07-27 | Boehringer & Soehne Gmbh | Procédé d'obtention de vanilline |
US7825267B2 (en) * | 2006-09-08 | 2010-11-02 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Synthesis of FR901464 and analogs with antitumor activity |
AR070865A1 (es) | 2008-03-18 | 2010-05-12 | Genentech Inc | Combinaciones de un conjugado anticuerpo- farmaco anti- her2 y agentes quimioterapeuticos y los metodos de uso |
AR080234A1 (es) | 2010-02-25 | 2012-03-21 | Marrone Bio Innovations Inc | Cepa bacteriana aislada del genero burkholderia y metabolitos pesticidas del mismo |
KR20160054627A (ko) * | 2011-08-27 | 2016-05-16 | 마론 바이오 이노베이션스, 인코포레이티드 | 부르크홀데리아 속의 단리된 박테리아 균주 및 그로부터의 살충 대사물-제제 및 용도 |
WO2014068443A1 (en) * | 2012-11-05 | 2014-05-08 | Pfizer Inc. | Spliceostatin analogs |
EP3071563B1 (en) | 2013-11-19 | 2023-04-19 | Purdue Research Foundation | Anti-cancer agents and preparation thereof |
-
2014
- 2014-11-19 EP EP14863201.1A patent/EP3071563B1/en active Active
- 2014-11-19 CN CN201480070416.9A patent/CN105829299A/zh active Pending
- 2014-11-19 AU AU2014353087A patent/AU2014353087B2/en active Active
- 2014-11-19 EA EA201691010A patent/EA035262B1/ru not_active IP Right Cessation
- 2014-11-19 JP JP2016532025A patent/JP6937578B2/ja active Active
- 2014-11-19 CN CN202110798232.6A patent/CN113461705A/zh active Pending
- 2014-11-19 ES ES14863201T patent/ES2943711T3/es active Active
- 2014-11-19 CA CA2931111A patent/CA2931111C/en active Active
- 2014-11-19 FI FIEP14863201.1T patent/FI3071563T3/fi active
- 2014-11-19 DK DK14863201.1T patent/DK3071563T3/da active
- 2014-11-19 US US15/038,027 patent/US10000505B2/en active Active
- 2014-11-19 MY MYPI2016000932A patent/MY189459A/en unknown
- 2014-11-19 MX MX2016006591A patent/MX2016006591A/es active IP Right Grant
- 2014-11-19 KR KR1020167016232A patent/KR102428737B1/ko active IP Right Grant
- 2014-11-19 PT PT148632011T patent/PT3071563T/pt unknown
- 2014-11-19 CN CN202110798234.5A patent/CN113773333A/zh active Pending
- 2014-11-19 WO PCT/US2014/066458 patent/WO2015077370A1/en active Application Filing
- 2014-11-19 PE PE2016000653A patent/PE20161240A1/es unknown
- 2014-11-19 BR BR112016011430-2A patent/BR112016011430B1/pt active IP Right Grant
-
2016
- 2016-05-15 IL IL245637A patent/IL245637B/en active IP Right Grant
- 2016-05-19 CL CL2016001209A patent/CL2016001209A1/es unknown
- 2016-05-19 PH PH12016500924A patent/PH12016500924A1/en unknown
-
2019
- 2019-07-05 JP JP2019125655A patent/JP6929903B2/ja active Active
-
2021
- 2021-04-19 IL IL282430A patent/IL282430A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR21C1059I2 (fr) | Compositions pharmaceutiques | |
CL2016001241A1 (es) | Nuevos compuestos pesticidas y usos | |
CL2015001924A1 (es) | Anticuerpos anti-pdgfr-beta y usos relacionados. | |
FR3006466B3 (fr) | . | |
DK3030262T3 (da) | Kombineret farmaceutisk sammensætning | |
UA29910S (uk) | Блендер | |
BR112015002790A2 (pt) | anticorpos asgpr e usos dos mesmos. | |
BR112016016289A2 (pt) | heteroaris e usos dos mesmos | |
BR112015001459A2 (pt) | anticorpos anti-kit e usos dos mesmos. | |
BR302014001376S1 (pt) | Configuração aplicada em bolsa. | |
BR302014000594S1 (pt) | Configuração aplicada em cápsula | |
BR112016011430A2 (pt) | agentes anticâncer e preparação dos mesmos. | |
FR3007989B1 (fr) | Autoinjecteur. | |
FR3014017B1 (fr) | Structure de securite | |
FR3013601B1 (fr) | Autoinjecteur. | |
DK3068505T3 (da) | Spillesystem og -fremgangsmåde | |
CL2014002083A1 (es) | Tionocarbamatos y procesos de preparacion. | |
FR3001302B1 (fr) | . | |
DK3003401T3 (da) | Farmaceutisk præparat | |
BR112015023621A2 (pt) | derivados de menopenem e usos dos mesmos | |
DK2983747T3 (da) | Lægemiddelindgivelsesindretning | |
DK2972363T3 (da) | Immunpotenserende nanobærerlægemiddel | |
FR3001303B1 (fr) | . | |
FR3012342B1 (fr) | Puzzle | |
TH1501001333B (th) | สารผสมกำจัดวัชพืชซึ่งประกอบรวมด้วยอะมิโนไพราลิด และไตรโคลไพร์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2014, OBSERVADAS AS CONDICOES LEGAIS |